SW106065|cas:62289-81-0|西域试剂

SW106065,99.78%

产品编号：Bellancom-124778| CAS NO：62289-81-0| 分子式：C₁₀H₈N₂OS| 分子量：204.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124778	￥1500.00	杭州北京（现货）
Bellancom-124778	￥2500.00	杭州北京（现货）
Bellancom-124778	￥4500.00	杭州北京（现货）
Bellancom-124778	￥6500.00	杭州北京（现货）
Bellancom-124778	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SW106065

产品介绍

SW106065 是恶性周围神经鞘瘤 (MPNST) 的凋亡 (apoptosis) 诱导剂。SW106065 以 EC₅₀ 为 1 µM 来抑制 sMPNST 细胞和其他模型中 MPNST 的 ATP 消耗。SW106065 可用于 MPNST 的研究。

生物活性

SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC₅₀ of 1 µM. SW106065 can be used for MPNST research.

体外研究

SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC₅₀ concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts.
SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M.
SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner. SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein.
SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	sMPNST cells
Concentration:	0.25 µM, 0.5 µM, 1 µM, 2.5 µM, and 5 µM
Incubation Time:	24 hours
Result:	Showed a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M.

RT-PCR

Cell Line:	sMPNST cells
Concentration:	0.25 µM, 0.5 µM, 1 µM, 2.5 µM, and 5 µM
Incubation Time:	24 hours
Result:	Decreased levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. Increased levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.

Western Blot Analysis

Cell Line:	sMPNST cells
Concentration:	0.25 µM, 0.5 µM, 1 µM, 2.5 µM, and 5 µM
Incubation Time:	24 hours
Result:	Decreased levels of Cyclin D1 protein.

体内研究
(In Vivo)

SW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCR-nu/nu female mice (6-7 week old) injected with MPNST cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; twice per day for 4 weeks
Result:	Reduced MPNST burden in a mouse allograft model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCR-nu/nu female mice (6-7 week old) injected with MPNST cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; twice per day for 4 weeks
Result:	Reduced MPNST burden in a mouse allograft model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCR-nu/nu female mice (6-7 week old) injected with MPNST cells
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; twice per day for 4 weeks
Result:	Reduced MPNST burden in a mouse allograft model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (489.60 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.8960 mL	24.4798 mL	48.9596 mL
5 mM	0.9792 mL	4.8960 mL	9.7919 mL
10 mM	0.4896 mL	2.4480 mL	4.8960 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。